Lophora, a clinical-stage CNS drug discovery company developing novel, next
generation 5HT2ARA medicines to treat a multitude of psychiatric disorders,
announced today that it has submitted a Clinical Trial Application (CTA) for its lead
drug program LPH-5. The CTA is directed towards a Phase I first-in-human study to
assess the safety, tolerability, pharmacokinetics and potential pharmacodynamic
profile of LPH-5.
“This study marks a significant step towards advancing our understanding of this
exciting, new class of CNS medicines. With convincing data and strong, granted
composition of matter patents Lophora is well positioned to advance not only LPH-
5 but also our second candidate LPH-48, a short-acting 5HT2ARA medicine to treat
a multitude of psychiatric disorders” said Bo Tandrup, Lophora’s Chief Executive
Officer.
“Low doses of LPH-5 do not trigger a psychedelic experience, but still show antidepressant
effect, so this new class of medicines can be impactful both within the
emerging psychedelic treatment paradigm (paired with psychotherapy), and a
traditional CNS treatment paradigm” said prof. Jesper Kristensen, Lophora’s
Founder and Chief Science Officer.